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ABSTRACT
DNA mismatch repair (MMR) enzymes act as proofreading complexes that 
maintains genomic integrity and MMR-deficient cells show an increased mutation 
rate. MMR has also been shown to influence cell signaling and the regulation of 
tumor development. MMR consists of various genes and includes post-meiotic 
segregation (PMS) 2 which is a vital component of mutL-alpha. In prostate, the 
functional role of this gene has never been reported and in this study, our aim was 
to investigate the effect of PMS2 on growth properties of prostate cancer (PCa) cells. 
Previous studies have shown PMS2 to be deficient in DU145 cells and this lack of 
expression was confirmed by Western blotting whereas normal prostatic PWR-1E 
and RWPE-1 cells expressed this gene. PMS2 effects on various growth properties of 
DU145 were then determined by creating stable gene transfectants. Interestingly, 
PMS2 caused decreased cell proliferation, migration, invasion, and in vivo growth; 
and increased apoptosis as compared to vector control. We further analyzed genes 
affected by PMS2 expression and observe the apoptosis-related TMS1 gene to be 
significantly upregulated whereas anti-apoptotic BCL2A1 was downregulated. These 
results demonstrate a functional role for PMS2 to protect against PCa progression by 
enhancing apoptosis of PCa cells.
INTRODUCTION
Prostate cancer (PCa) ranked as the most frequently 
diagnosed malignancy among men in the United States of 
America with an estimated 233, 000 new incidences in the 
Year 2014 [1]. With an annual mortality rate of 29, 480, 
this malignancy ranked second in cancer deaths [1]. As 
an aging disease, invasive PCa is expected to occur in 
1 in 43 of those aged 50 to 59, 1 in 16 aged 60 to 69, 
and 1 in 9 aged 70 years and older [1]. PCa is generally 
treatable with androgen-deprivation therapy however 
there is a high recurrence to an androgen-independent and 
metastatic state of this cancer that leads to death within 
several years. There are no effective therapies currently to 
cure androgen-independent PCa and thus, new prognostic 
markers and effective treatment strategies are desired.
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A factor that can lead to PCa is DNA mismatch 
mutations and to overcome their harmful effects, the 
cell has the DNA mismatch repair (MMR) system that 
is able to correct these lesions. Deficiencies in the MMR 
pathway can result in higher rates of mutation or genetic 
instability that can cause defects in genes that regulate 
cell proliferation and death [2], thereby increasing 
susceptibility to cancers. Alternatively, MMR genes are 
capable of sensitizing cells toward DNA lesions and 
trigger apoptosis, cell cycle arrest, and cell death [3, 4]. 
Thus, MMR is vital for proper cellular function and health 
of the individual.
Among diseases known for mutations in MMR is 
hereditary non-polyposis colorectal cancer (HNPCC) and 
interestingly, clinical reports have shown PCa to arise 
from men afflicted with HNPCC [5, 6]. In fact, the lifetime 
risk of PCa was calculated to be double among individuals 
with HNPCC and defective MMR as compared to the 
general population [6]. In a study conducted in Norway, 
men described as carriers or obligate carriers of MMR 
mutation developed PCa at a significantly higher rate than 
that expected to occur by chance in the population [7]. 
These men were significantly younger at the time of 
diagnosis and with higher Gleason scores of 8 to 10 
compared to men diagnosed prior to 70 years of age in 
the population. Further analysis calculated the cumulative 
risk of PCa by age 70 years to be 30% in MMR gene 
mutation carriers compared to 8% in the population. In 
another study evaluating a colon cancer family registry of 
764 carriers of MMR gene mutations, a higher risk for PCa 
was observed compared to the general population with a 
standardized incidence ratio of 2.05 and 95% confidence 
interval of 1.23 to 3.01 [8]. Thus deficiencies of the MMR 
process can lead to PCa.
The MMR system consists of various proteins 
and among the MutL homologues is the post-meiotic 
segregation (PMS2) gene [9, 10]. PMS2 is located in 
chromosome 7p22 region, consists of 15 exons and is 
roughly 16 kilobases in length [11]. PMS2 is a nuclear 
protein that is composed of 862 amino acids with a size 
of 95.8 kDa. PMS2 heterodimerizes with MLH1 to form 
MutL alpha and together with MutS heterodimers (alpha 
or beta) and other co-factors, repairs DNA mismatches 
and insertion-deletion mispairs formed during DNA 
replication or recombination [10, 12]. PMS2 appears to 
have endonucleolytic activity during the repair process 
as Kadyrov et al. [13] identified a motif responsible for 
this role.
Hundreds of mutations and polymorphisms have 
been identified among the various MMR genes and 
includes the PMS2 gene [14]. Interestingly though not 
significant, PMS2 mutation carriers were observed to 
have more extra-colonic cancers [15]. In prostate, defects 
of PMS2 in cancer cell lines have been documented in 
prior studies. Among the first reports was the PCa line 
DU145 where Boyer et al. [16] identified a missense 
mutation in the PMS2 gene after demonstrating reduced 
MMR activity and microsatellite instability, an indicator 
of MMR deficiency. Chen et al. [17] confirmed genomic 
instability in DU145 cells as PMS2 protein expression was 
lacking. In fact, they observed this gene to be deficient 
and correlated with genomic instability in a wider range of 
PCa cell lines compared to other MMR genes. Martin et al. 
[18] also found no PMS2 protein in these DU145 cells. A 
prior study from our laboratory [19] showed the DU145 
and LNCaP cell lines to have none to low levels of PMS2 
protein expression and these had reduced DNA repair 
activity as compared to the MMR proficient Hela cells.
PMS2 expression has also been studied in 
prostate tissue. Reports by Chen et al. [17, 20] found 
that in the normal prostate gland region, PMS2 protein 
was predominantly detected in the nuclei of glandular 
luminal epithelium, basal cells, and some stromal cells. 
This pattern of PMS2 expression was also observed 
in the normal adjacent region of prostate tumor tissue. 
In malignant prostate cells however, PMS2 levels were 
found to be less than that observed in normal adjacent 
areas and in fact, more tumor foci showed loss of PMS2 
compared to other MMR genes. Other studies also 
showed reduced PMS2 protein expression in prostate 
tumor regions as compared to normal adjacent [20, 21]. 
Additionally, PMS2 expression including both RNA [21] 
and protein [21, 22] were found to be much lower in PCa 
when compared to benign prostatic hyperplasia (BPH) 
tissue; and a significant inverse correlation between 
Gleason score and PMS2 expression was observed in PCa, 
making it a good marker of progression [21, 22]. In fact, 
PMS2 protein expression was observed to be the most 
downregulated in PCa among the MMR proteins [21].
The PMS2 gene is thus shown to be reduced 
in PCa cell lines and tissues. Therefore in this study, 
we characterized the functional role the PMS2 gene 
plays in PCa cells. Our results are the first to show 
that re-expressing the PMS2 gene in PCa cells causes 
inhibition of cell growth both in vitro and in vivo. Also, we 
demonstrate PMS2 to enhance apoptosis and induce TMS1 
and suppress BCL2A1 genes as a possible mechanism for 
its protective role in PCa cells.
RESULTS
Prostate cancer cell line DU145 is PMS2 deficient
Prior studies have established DU145 cells to 
be PMS2-deficient [17–19] and thus, we selected this 
cancerous cell line for further studies. Initially, we 
confirmed protein expression levels of PMS2 in DU145 
cells and as a comparison, measured expression in 
the normal prostate epithelial cell lines, PWR-1E and 
RWPE-1. Figure 1 show no protein detected for PMS2 
in DU145 cells whereas levels were high in RWPE-1 and 
low in PWR-1E.
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Effect of PMS2 re-expression on cell 
proliferation, migration and invasion
Absence of PMS2 protein in DU145 cells led us to 
examine whether re-expressing PMS2 affects the growth 
of these cells. To do this, we established DU145 cell 
lines that stably express PMS2. As shown in Figure 2A, 
PMS2 protein was detected by Western blotting in stable 
PMS2-transfected DU145 cells (clone 1) but not in mock 
or vector control cells. A second clone also demonstrated 
a protein band (not shown). To determine the effects 
of PMS2 on cellular properties, we conducted various 
functional analyses using both clones. MTS assay showed 
that cell proliferation was reduced 41% in clone #1 and 
29% in clone #2 after 72 hours in DU145 cells expressing 
PMS2 compared to vector control (P < 0.01) (Figure 2B). 
In accordance, silencing normal PWR-1E cells with two 
PMS2 siRNAs caused increased proliferation (P < 0.08) 
(Supplementary Figure 1). Wound healing assay 
demonstrated significant inhibition of cell migration in 
PMS2-stable compared with vector-transfected DU145 
cells after 24 hours (47% closure clone #1 and 42% 
closure clone #2 versus 73% closure for control, P < 0.01) 
(Figure 2C). Matrigel invasion assay also showed that the 
number of invading cells was significantly decreased in 
PMS2 transfectants with absorbance at 560 nm of 0.14 
(clone #1) and 0.15 (clone #2) compared with vector 
control having absorbance of 0.19 (P < 0.01) (Figure 2D). 
These results indicate PMS2 to play an important role in 
reducing tumor cell proliferation, migration and invasion.
Effect of PMS2 expression on 
tumorigenicity in vivo
To validate the suppressive effect of PMS2 under 
in vitro conditions, we also determined effects of PMS2 on 
tumor growth in animal models. Stable PMS2 and pCMV 
DU145 cells were subcutaneously injected into nude mice. 
We observed that expression of PMS2 inhibited DU145 
cell tumor formation throughout the duration which lasted 
5 weeks whereas tumors grew rapidly and were visible 
in pCMV animals (P < 0.05) (Figure 3). These results 
suggest PMS2 suppresses PCa cell growth in vivo.
PMS2 influences cellular apoptosis
Since PMS2 restoration significantly inhibited cell 
growth and progression of DU145 cells both in vitro and 
in vivo, we hypothesized that its expression may induce 
apoptosis. Figure 4 shows that the apoptotic and early 
apoptotic fractions (upper right and lower right quadrants 
of biparametric histograms, respectively) were increased 
in PMS2-transfectants compared to vector control after 
72 hours of growth. Total apoptosis levels were 10.9% 
versus 19.7% (P < 0.01) and 16.1% (P < 0.05) for 
pCMV versus PMS2-expressing clone #1 and #2 cells, 
respectively (Figure 4).
PMS2 induces TMS1 and inhibits BCL2A1 genes
The pro-apoptotic role for PMS2 observed suggests 
that apoptotic pathways are affected. We thus performed 
array analyses to determine which apoptotic genes are altered 
due to PMS2 in DU145 cells. Table 1 displays genes that 
are elevated or reduced two-fold or greater. Up-regulation 
of the Target of Methylation induced Silencing (TMS1) 
gene due to PMS2 was confirmed by real-time PCR using 
TaqMan probes as a 3.2-fold increase was observed relative 
to pCMV controls (P < 0.01) (Figure 5A). On the contrary, a 
reduction of over 90% of B-cell lymphoma 2-related protein 
A1 (BCL2A1) due to PMS2 was confirmed (P < 0.01) 
(Figure 5B). Other genes did not differ however, between 
PMS2
GAPDH
Figure 1: PMS2 expression is downregulated in DU145 PCa cells. Prostatic cell lines were grown in culture dishes for two 
days and underwent Western analyses. Shown is a representative immunoblot of PMS2 protein expression in DU145 and normal prostate 
epithelial PWR-1E and RWPE-1 cells. GAPDH was used as loading control.
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pCMV and PMS2 when analyzed by real-time PCR. 
These results indicate TMS1 and BCL2A1 to moderate the 
apoptotic effects of PMS2 in PCa cells.
DISCUSSION
The MMR system recognizes and corrects mis-
incorporated nucleotides and insertion/deletion mis-pairs 
formed during DNA replication [9, 10]. Loss of proteins 
critical in this repair process however, can result in 
genetic alterations that may ultimately lead to cancer. 
MMR deficiency also predisposes cells of the body to an 
increased frequency of inactivating mutations in genes 
important for suppressing carcinogenesis [2]. Besides 
their established role in DNA repair, MMR genes are also 
involved in cell cycle checkpoints and apoptosis stimulated 
by DNA damage [3, 4]. Resistance to apoptosis and cell 
death were shown in cells deficient in MMR genes when 
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Figure 2: Re-expression and tumor suppressive effect of PMS2 on DU145 cells. A. Ectopic expression of PMS2. DU145 cells 
stably transfected with either PMS2 or empty vector (pCMV) along with mock (parental DU145 cells treated with transfection reagent alone) 
were grown for 48 hours and underwent Western analyses. GAPDH was used as loading control. Note: Clone #2 (not shown) displayed a band 
similar in intensity to #1. B. Cell proliferation as analyzed by the MTS cell proliferation assay 72 hours after plating cells. Results are expressed 
as % and normalized to pCMV control. C. Cell migration as measured by wound healing assay. A wound was formed by scraping culture 
dishes using a pipet tip and closure measured after 24 hours. Left: Representative images of wound healing assay are shown. Right: Migration 
expressed as % closure of wound. D. Cell invasiveness as measured using Matrigel. Cells were placed onto transwell membrane and allowed 
to invade for 24 hours. Left: Representative images of invading cells are shown. Right: Cell invasiveness as measured by absorbance (Abs) at 
560 nm. Data are presented as mean ± SEM of at least three experiments; **P < 0.01 PMS2 versus pCMV.
Oncotarget16345www.impactjournals.com/oncotarget
pCMV    PMS2 #1
*0
200
400
600
800
pCMV PMS2 #1
Tu
m
or
 S
iz
e 
(m
m
3 )
Figure 3: Expression of PMS2 suppresses growth of DU145 cells in vivo. Athymic nude mice were injected subcutaneously 
with stable PMS2 or pCMV-transfected DU145 cells and growth determined after 35 days. Left: Representative image of tumors in mice. 
Right: Tumor size (mm3). Data are presented as mean ± SEM of five mice per group; *P < 0.05 PMS2 versus pCMV.
Figure 4: PMS2 expression upregulates apoptosis. Stable PMS2-expressing and vector control DU145 cells were grown for 
72 hours and apoptosis was measured by flow cytometric analyses. Top: Representative biparametric histogram showing cell population in 
early (bottom right quadrant) and late (top right quadrant) apoptotic, and viable (bottom left quadrant) states for each treatment. Bottom: 
Total apoptosis %. Bar graph is mean ± SEM of three experiments; **P < 0.01, *P < 0.05 PMS2 versus pCMV.
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Table 1: Apoptosis-related genes increased or decreased 2-fold or greater due to expression of 
PMS2 in DU145 clone #1 cells
Gene Fold change
TMS1 5.3262
IGF1R 2.1167
HRK 2.0917
CD27 2.083
BCL2A1 −3.3694
CASP1 −5.9844
CASP4 −6.6332
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Figure 5: PMS2 induces TMS1 and inhibits BCL2A1 expression in DU145 cells. Stable PMS2-expressing and vector control 
DU145 cells were grown and expression of A. TMS1 and B. BCL2A1 was determined by real-time PCR. Levels are normalized to vector 
control. Data are presented as mean ± SEM of three experiments; **P < 0.01 PMS2 versus pCMV.
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treated with DNA damaging chemotherapeutic agents 
[23, 24]. The MMR system is thus vital for maintaining 
cell integrity and disease prevention.
Among the various MMR genes, the PMS2 gene has 
been relatively understudied in relation to cancer risk [25]. 
This gene however, has been shown to play an important 
role in cellular and repair activity as its deficiency has 
been shown to cause various aberrations. Early studies 
in S. cerevisiae find repair of mismatches to be impaired 
due to mutant PMS gene [26]. Transfection of dominant 
negative fragment of PMS2 into microsatellite stable cells 
caused an increase in microsatellite instability [20]. In 
PMS2-deficient transgenic mice, a much higher rate of 
mutation was observed after exposure to ionizing radiation 
[27] as well as thymic lymphomas after treatment with 
MNU [28] when compared to wildtype animals. A protein 
truncate leading to deficiency of PMS2 caused a lack 
of repair function in breast cancer cells [29]. In Hela 
variants lacking PMS2 protein, extracts were ineffective 
in correcting base mispair but upon introducing wildtype 
chromosome 7 into cells, correction of the repair defect 
was restored [30]. In endometrial cancer line HEC-1-A, 
PMS2 was observed lacking and defective in correcting 
a variety of mismatches [31] and transfection of PMS2 
caused these cells to increase microsatellite stability and 
repair of mismatches [32]. In glioblastoma cells resistant 
to temozolomide treatment, a reduction in PMS2 protein 
was observed and knockdown of PMS2 in parental cells 
conferred this resistance [33]. The genetic status of PMS2 
in cells thus has high impact in cellular function.
In prostate tissue, PMS2 has been shown to be 
downregulated in tumor regions as compared to normal 
areas [17, 20, 21] and benign hyperplasia [21, 22]. Given 
that PMS2 can affect cell growth parameters, we explored 
the functional significance the PMS2 gene has on PCa 
cells which has never been done. PMS2 protein expression 
in the DU145 cell line has previously been shown to be 
downregulated [17–19] and our results confirmed this 
lack of expression. The nature of the loss of PMS2 in this 
cell line is not known. A comprehensive analysis of MMR 
mRNA transcripts reported in databases and the literature 
by Thompson et al. [34] found several alternative forms of 
PMS2 that could lead to protein of varying lengths. It was 
demonstrated that in breast, nonsense mutations leading 
to truncate PMS2 protein occurred in the neoplastic 
transformation of epithelial cells in vitro [29] and tissue 
specimens [35] and interestingly, truncating mutations 
have been shown to nullify expression of PMS2 protein 
[36]. The deficiency of PMS2 in DU145 also impacts 
cellular genetics as Boyer et al. [16] and Yeh et al. [19] 
reported reduced MMR activity, and Boyer et al. [16] 
observed microsatellite instability in these cells. Thus, 
DU145 PCa cells are an ideal cell line to determine 
functional effects of PMS2 by gene re-expression.
By expressing the PMS2 gene in DU145 cells, we 
observed that this gene caused a significant reduction 
in proliferation, migration, and invasive properties of 
this PCa cell line. A similar effect was observed in vivo 
as PMS2-expressing cells inhibited tumor growth. This 
repressive activity was found to be due to apoptosis as 
PMS2 cells had a much higher rate compared to that 
of vector control. The apoptotic environment was also 
supported by an observed rise in TMS1 gene, suggesting 
the presence of caspase proteins [37] as well as reduction 
of BCL2A1, indicating the release of pro-apoptotic BCL2-
related and BH3-only proteins [38]. Thus, PMS2 plays 
a tumor suppressor role in PCa cells and this effect is 
substantiated by enhanced proliferation due to silencing 
of this gene as observed in normal PWR-1E cells. In 
concordance with our results, PMS2 has been shown by 
others to play an important role in apoptosis. Transfection 
of PMS2 in Hela cells caused a dramatic increase of 
cisplatin-induced apoptosis and interestingly, caspase-3 
activity was significantly increased in these cells [39]. 
In animal models, treating PMS2 null mice with NMNU 
or temozolomide caused a reduced apoptotic response 
compared to wildtype [40] and Zeng et al. [41] observed 
cells derived from null mice to have reduced levels 
of apoptosis after infrared exposure, with effect being 
independent of p53. Furthermore, in adenocarcinoma 
specimens from patients, those with reduced PMS2 
expression had lower apoptotic ability in nearby tissue 
samples [42].
The pathway by which apoptosis is induced by 
PMS2 in PCa cells may be through TMS1 as this gene was 
observed to be the most upregulated. TMS1 consists of 
two protein interacting domains which are a pyrin domain 
(PYD) and a caspase recruitment domain (CARD) [43]. 
This gene is a tumor suppressor and can cause apoptosis 
by interacting with proteins such as BAX, BID, p53, 
and caspases [37]. The TMS1 gene is highly methylated 
with transcriptional repression in various cancers [37]. 
In prostate, TMS1 is observed to be downregulated in 
high grade PIN and cancer compared to BPH and normal 
controls [44], and this reduction has been shown to be due 
to promoter methylation [45, 46]. In prostatic cell lines, a 
similar tendency exists as TMS1 expression is silenced in 
cancer cells including DU145 and methylated, whereas in 
PrEC (primary prostate epithelial cells), benign BPH-1, 
and normal RWPE-1 cells, TMS1 is highly expressed 
and unmethylated [45–47]. Since TMS1 was observed 
to be upregulated in PMS2-treated DU145 cells, it is 
thus apparent that PMS2 is capable of reversing the 
methylation status and inducing expression of TMS1 and 
warrants further investigation.
In addition to TMS1, apoptosis due to PMS2 may 
also be caused by downregulation of BCL2A1. BCL2A1 
is an anti-apoptotic gene that affects the intrinsic apoptotic 
pathway. BCL2A1 binds and suppresses various apoptotic 
agents such as BAK, BID, BIM, PUMA and NOXA [38] 
and thus, reduction of this gene can result in discharge 
of these factors culminating in apoptosis. Various cancers 
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such as gastric [48] stomach [48], colon [48, 49], and 
breast [49] have been shown to have elevated levels of 
BCL2A1. In prostate, tissue expression levels of BCL2A1 
were observed to be increased in cancerous versus 
normal [49], metastatic versus non-metastatic [50], high 
versus low stages [50], and was undetectable in BPH [50]. 
Interestingly in cell lines, BCL2A1 was also highly 
expressed in cancerous cells that include DU145 [50]. 
Thus, downregulation of BCL2A1 by PMS2 observed 
in our study strongly suggests PMS2 to contribute to the 
apoptotic effect of PCa cells; and this effect may be in 
concert with the upregulation of TMS1.
In summary, this is the first report that shows PMS2 
to display a protection against PCa by inhibiting cell 
proliferation, migration, and invasion in vitro as well as 
tumor growth in vivo. PMS2 induced apoptosis and this 
was supported by a rise in TMS1 and fall in BCL2A1. 
Thus, we conclude that PMS2 plays a tumor suppressor 
role by enhancing apoptosis in PCa cells.
MATERIALS AND METHODS
Cell lines and reagents
Human PCa cell line DU145 and non-malignant 
epithelial prostate cell lines PWR-1E and RWPE-1 
were purchased from American Type Culture Collection 
(Manassas, VA). Keratinocyte serum-free medium, bovine 
pituitary extract and human recombinant epidermal 
growth factor were purchased from Invitrogen (Carlsbad, 
CA). RPMI 1640, Opti-minimum essential medium and 
penicillin/streptomycin were obtained from the UCSF 
Cell Culture Facility (San Francisco, CA). Fetal bovine 
serum (FBS) was a product of Atlanta Biologicals 
(Lawrenceville, GA).
Cell culture
DU145 cells were cultured in RPMI 1640 medium 
supplemented with 10% FBS. PWR-1E and RWPE-1 
cells were cultured in keratinocyte growth medium 
supplemented with 5 ng/mL human recombinant epidermal 
growth factor and 0.05 mg/mL bovine pituitary extract. 
All cell lines were maintained at 37°C in a humidified 
atmosphere composed of 5% CO2 and 95% air.
Western blot analysis
Whole cell extracts from cultured cells were 
prepared using radioimmunoprecipitation assay 
buffer (Thermo Scientific, Rockford, IL) containing 
protease inhibitor cocktail (Roche Diagnostics, Basel, 
Switzerland). Protein quantification was done using a 
BCA protein assay kit (Thermo Scientific) according 
to the manufacturer’s instructions. Total protein 
(20 μg) was loaded onto 4–12% bis–tris gels with 
3-(N-morpholino) propanesulfonic acid buffer and 
separated by a NuPAGE electrophoresis system 
(Invitrogen). Protein was transferred to Invitrogen™ 
polyvinylidene difluoride and immunoblotting was 
carried out according to standard protocols. Monoclonal 
antibody against PMS2 was purchased from Origene 
Technologies (Rockville, MD) and monoclonal antibody 
against GAPDH (Santa Cruz Biotechnology, Santa Cruz, 
CA) was used to confirm equal loading. The membrane 
was washed and then incubated with secondary 
antibodies conjugated to horseradish peroxidase 
(Cell Signaling Technology). Protein complexes were 
visualized with the Echo-chemiluminescence (ECL) 
Detection System (GE Healthcare, Little Chalfont, 
UK) using the Chemidoc Imaging System (Bio-Rad 
Laboratories, Hercules, CA).
Real-time quantitative polymerase 
chain reaction
Total RNA was extracted from DU145, PWR-1E and 
RWPE-1 cells using the RNeasy Mini kit (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions. Extracted 
RNA was reverse-transcribed into complementary DNA 
(cDNA) using iScript cDNA Synthesis kit (Bio-Rad) and 
TaqMan MicroRNA Reverse Transcription kit (Applied 
Biosystems, Foster City, CA). Quantitative real-time PCR 
analysis was performed with an Applied Biosystems Prism 
7500 Fast Sequence Detection System using TaqMan 
Universal PCR master mix according to the manufacturer’s 
protocol (Applied Biosystems). Levels of RNA expression 
were determined using the 7500 Fast System SDS software 
version 1.3.1 (Applied Biosystems). PCR parameters 
for cycling were as follows: 95ºC for 20 seconds, then 
40 cycles of 95ºC for 3 seconds and 60ºC for 30 seconds. 
All reactions were done in a 10 μL reaction volume in 
triplicate. The data were analyzed using the delta-delta Ct 
method to calculate the fold-change. TaqMan probes and 
primers for PMS2 (assay ID: Hs00241053_m1), TMS1 
(Hs01547324_gH), BCL2A1 (Hs00187845_m1), and 
GAPDH (Hs02758991_g1) were obtained from Applied 
Biosystems. GAPDH was used as internal control. For 
array analyses, expression of apoptosis-related genes was 
determined using the Human Apoptosis RT2 Profiler PCR 
Array (Qiagen) per manufacturer’s instructions.
Establishment of DU145 cells stably 
expressing PMS2
DU145 cells were transfected with pCMV6-ENTRY 
vector expressing the C-terminally Myc and Flag-tagged 
human PMS2 cDNA as well as empty pCMV6-ENTRY 
vector as a control (Origene) using X-treme Gene HD 
transfection reagent (Roche Diagnostics, Indianapolis, 
IN) according to the manufacturer’s protocol. Clones 
were selected using 500 μg/ml of G418 (Invitrogen). 
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Colonies resistant to G418 appeared within 2 weeks and 
single colonies were picked and then expanded for another 
3 weeks to make stable clone stock cells.
Small interfering RNA transfection
Cells grown to 30–50% confluence were treated 
with two different sets of small interfering RNA (siRNA) 
duplexes specific for human PMS2 (siPMS2) or negative 
control siRNA (Life Technologies) by transfection 
using Lipofectamine RNAiMAX transfection reagent 
(Life Technologies) as described by the manufacturer. 
Knockdown efficiency was evaluated by real-time PCR 
for the two siPMS2s at different concentrations and the 
optimal condition selected was 10 nM.
Cell proliferation assay
An MTS based assay was utilized to determine 
cell proliferation. Cells were plated in triplicate in 
96-well microplates at a density of 5 × 103 cells per 
well. At the desired time point, the number of viable 
cells was determined by adding CellTiter 96 AQueous One 
Solution reagent (Promega, Madison, WI) to each well 
and measuring the absorbance at 490 nm on a SpectraMax 
190 plate reader (Molecular Devices, Sunnyvale, CA). 
Results were expressed as the percentage of optical density 
with absorbance of control cells being 100%.
Migration and invasion assays
Cell migration was evaluated by a wound-
healing assay. Cells were plated in six-well dishes and 
monolayers were scraped using a P-20 micropipette tip. 
The width of the initial gap (0 hour) and the residual 
gap 24 hours after wounding were calculated from 
photomicrographs taken using a Nikon Eclipse TS100 
microscope (Technical Instruments, Burlingame CA). Cell 
invasion properties were measured by a procedure using 
the CytoSelect Invasion assay (Cell Biolabs, San Diego 
CA) along with modified Boyden chambers consisting 
of transwell-precoated Matrigel membrane filter inserts 
with eight micron pores in 24-well tissue culture plates 
(BD Biosciences, Bedford, MA). Minimum essential 
medium containing 10% FBS in the lower chamber served 
as the chemo-attractant. After 24 hours, invasive cells were 
stained and observed by photomicrographs taken with the 
Nikon microscope and quantified using the SpectraMax 
plate reader at absorbance of 560 nm.
In vivo tumor growth
All animal care was in accordance with the 
guidelines and this study was approved by the San 
Francisco Veterans Affairs IACUC (Institutional Animal 
Care and Use Committee). Animal users completed 
training programs to handle and work with mice 
through AALAS (American Association for Laboratory 
Animal Science) prior to animal experiments. For 
the subcutaneous xenograft mouse model, DU145 
cells (5 × 106) stably transfected with PMS2 or empty 
pCMV6-ENTRY vector were suspended in 100 μL RPMI 
1640 medium and subcutaneously injected into the right 
backside flank of five week old female nude mice (strain 
BALB/c nu/nu; Charles River Laboratories, Wilmington, 
MA). Five nude mice were used per treatment group and 
tumor growth was examined after 35 days. Tumor volume 
was calculated on the basis of width (x) and length (y) 
using the formula: x2y/2, where x < y.
Apoptosis assay
Apoptosis was analyzed with an annexin 
V-fluorescein isothiocyanate (FITC)/7-amino-actinomycin 
D staining system obtained from BD Biosciences (San 
Diego, CA). Briefly, prostate cells were harvested 
and resuspended in binding buffer at a concentration 
of 1 × 106 cells/ml. For each assay, 1 × 105 cells were 
incubated with 5 μl of annexin V-FITC and 5 μl of 
7-amino-actinomycin D in the dark for 15 min at room 
temperature. After adding 400 μl of binding buffer, samples 
were analyzed within an hour by a Cell Lab Quanta™ SC 
MPL flow cytometer (Beckman Coulter, Fullerton, CA).
Statistical analyses
Values in Figures are presented as the 
mean ± standard error of mean (SEM) based on results 
obtained from at least three independent experiments. For 
in vivo studies, results are based on five animals per group. 
The relationship between variables was analyzed using 
the non-parametric Mann-Whitney U test or two-tailed 
Student’s t-test. All analyses were performed using Expert 
StatView (version 4, SAS Institute, Cary, NC).
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